Skip to main content
. 2021 Jul 13;9(1):HEP40. doi: 10.2217/hep-2020-0031

Table 2. . Disease control rate.

DCR TACE + B TACE p-value
1 month 100% 84% 0.043†
3 months 97 % 76% < 0.001†
6 months 72% 63% 0.174
†

p < 0.05.

B: Bevacizumab; DCR: Disease control rate; TACE: Transarterial chemoembolization.